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Abstract
Background: Time to antibiotic administration is a key element in sepsis care; however, it is difficult to implement
sepsis care bundles. Additionally, sepsis is different from other emergent conditions including acute coronary
syndrome, stroke, or trauma. We aimed to describe the association between time to antibiotic administration and
outcomes in patients with severe sepsis and septic shock in Japan.
Methods: This prospective observational study enrolled 1184 adult patients diagnosed with severe sepsis based on
the Sepsis-2 criteria and admitted to 59 intensive care units (ICUs) in Japan between January 1, 2016, and March 31,
2017, as the sepsis cohort of the Focused Outcomes Research in Emergency Care in Acute Respiratory Distress
Syndrome, Sepsis and Trauma (FORECAST) study. We compared the characteristics and in-hospital mortality of
patients administered with antibiotics at varying durations after sepsis recognition, i.e., 0–60, 61–120, 121–180, 181–
240, 241–360, and 361–1440 min, and estimated the impact of antibiotic timing on risk-adjusted in-hospital
mortality using the generalized estimating equation model (GEE) with an exchangeable, within-group correlation
matrix, with “hospital” as the grouping variable.
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Results: Data from 1124 patients in 54 hospitals were used for analyses. Of these, 30.5% and 73.9% received
antibiotics within 1 h and 3 h, respectively. Overall, the median time to antibiotic administration was 102 min
[interquartile range (IQR), 55–189]. Compared with patients diagnosed in the emergency department [90 min (IQR,
48–164 min)], time to antibiotic administration was shortest in patients diagnosed in ICUs [60 min (39–180 min)] and
longest in patients transferred from wards [120 min (62–226)]. Overall crude mortality was 23.4%, where patients in
the 0–60 min group had the highest mortality (28.0%) and a risk-adjusted mortality rate [28.7% (95% CI 23.3–
34.1%)], whereas those in the 61–120 min group had the lowest mortality (20.2%) and risk-adjusted mortality rates
[21.6% (95% CI 16.5–26.6%)]. Differences in mortality were noted only between the 0–60 min and 61–120 min
groups.
Conclusions: We could not find any association between earlier antibiotic administration and reduction in in-
hospital mortality in patients with severe sepsis.
Keywords: Sepsis, Antibiotic, Bundle, Protocols
Key points
 In Japan, one third of the patients received
antibiotics within 1 h and three fourths within 3 h of
sepsis recognition.
 Our descriptive results do not support early
antibiotic administration, i.e., within 1 h after
diagnosis, for reducing in-hospital mortality in pa-
tients with severe sepsis and septic shock.
Background
Time to antibiotic administration is a key element in
sepsis care, and the Surviving Sepsis Campaign (SSC)
guidelines (2004, 2008, 2012, and 2016) have repeatedly
recommended initiating empirical broad-spectrum ther-
apy within 3 h from triage or sepsis recognition [1–4].
However, the updated 2018 SSC guidelines recommend
a 1-h window for antibiotic administration following the
recognition of sepsis as a reasonable approach [5]; this
update has been significantly debated, and it remains
controversial [6]. Although it would be impossible to
argue against appropriate and timely antibiotic therapy
for sepsis considering its time-sensitive nature, sepsis is
different from other emergent conditions such as acute
coronary syndrome, stroke, or trauma. Specifically, its
recognition by healthcare providers within 1 h of presen-
tation may be difficult to achieve in real-life settings be-
cause of vague presenting symptoms and the fact that its
exact onset is mostly unobservable. Further, the only
randomized controlled trial (RCT) that evaluated early
antibiotic use in patients with suspected infection failed
to reduce mortality, although this was in the pre-
hospital setting [7].
We prospectively evaluated the characteristics and
management of patients with severe sepsis in the Fo-
cused Outcomes Research in Emergency Care in Acute
Respiratory Distress Syndrome, Sepsis, and Trauma
(FORECAST) study in Japan [8]. We then used the
FORECAST database to describe the association be-
tween time to antibiotic administration and outcomes in
patients with severe sepsis and septic shock treated in
real-world clinical settings.
Methods
The study protocol was reviewed and approved by the
ethics committee of all participating institutions in the
Japanese Association for Acute Medicine (JAAM) study
group, Japan (IRB No.014-0306 on Hokkaido University,
a representative institution for FORECAST). Obtaining
an informed consent from a study participant was
waived under the approval of the ethics committees.
Design and setting
This is a predefined secondary analysis of the FORE-
CAST study. We predefined the secondary analyses
when we set variables of the FORECAST study. It se-
lected a cohort of patients with severe sepsis and septic
shock who were registered in the FORECAST study,
which was a multi-center, prospective data collection
study on acutely ill patients that included those with
acute respiratory distress syndrome, sepsis, and trauma.
The FORECAST study obtained data from patients ad-
mitted to 59 intensive care units (ICUs) in Japan and
was conducted from January 1, 2016, to March 31, 2017.
Participants
We included adult patients (≥ 16 years) diagnosed with
severe sepsis and septic shock based on the Sepsis-2 cri-
teria published in 2003 [9] and admitted to the ICU.
The exclusion criteria were unfavorable sustained life-
care or post-cardiopulmonary arrest resuscitation status
at the time of sepsis recognition, missing data on anti-
biotic timing or in-hospital mortality, or time to anti-
biotic use > 1440 min.
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Data collection
Relevant patient data, originally compiled by the FORE-
CAST investigators, were obtained from the FORECAST
database. Hospital information obtained included num-
ber, specialty, type of facility and staff, number of pa-
tients, and number of beds. Patient data, collected as
part of the clinical workup, included demographic char-
acteristics of patients, organ dysfunctions, sepsis-related
severity scores, time to antibiotic administration, in-
hospital mortality, 28-day mortality, ICU-free days,
ventilator-free days (VFD), and length of hospital stay.
Additionally, we obtained data on compliance with
established sepsis care bundles, such as measurement of
the initial serum lactate levels within 3 h.
Data definitions
Sepsis care bundles were defined according to the SSC
guidelines (2012) [3] as to whether all bundle elements
were achieved within the appropriate time frame (i.e., 3
or 6 h) and if they adhered to indications (i.e., septic
shock or lactate level > 4mmol/L). For all patients,
protocol initiation time was defined as the time of sepsis
recognition at the emergency department (ED), ward, or
ICU. Sepsis recognition was a clinical judgment, wherein
a physician-in-charge had suspected sepsis at the initial
evaluation. Timestamp was recorded in the database by
a physician-in-charge. Patients with antibiotic before ar-
rival were recognized as patients with infection but not
sepsis. After arrival, time would start when a physician-
in-charge recognized a patient with sepsis. Time from
sepsis recognition to initiation of antibiotics (time to
antibiotic) was divided into six groups defined as 0–60,
61–120, 121–180, 181–240, 241–360, and 361–1440
min. Septic shock was defined based on the Sepsis-2 cri-
teria [9], and VFD was defined as the number of days
within the first 28 days after hospital admission during
which a patient was able to breathe without a ventilator.
VFD for patients who died during the study period was
listed as 0. ICU-free days were similarly calculated.
Analysis
The primary outcome was in-hospital mortality. Second-
ary outcomes were VFD and ICU-free days. The expos-
ure was time to antibiotic. Because the missing data
were low, no assumptions were made for this factor.
Descriptive statistics included frequency and percent-
age for categorical variables and mean ± standard devi-
ation (SD) or medians and interquartile range (IQR) for
continuous variables, as appropriate. We compared base-
line characteristics and outcomes among patients with
severe sepsis in the six time to antibiotic therapy groups
(0–60, 61–120, 121–180, 181–240, 241–360, and 361–
1440 min) using analysis of variance, Kruskal-Wallis test
or chi-square test, as required.
The impact of antibiotic timing on risk-adjusted hos-
pital mortality was estimated using the generalized esti-
mating equation (GEE) model with an exchangeable
within-group correlation matrix where the hospital was
the panel or grouping variable. The following covariates
were specified a priori based on clinical experience and
prior studies: patient age, gender, admission source (ED,
ward, or in ICU), Charlson comorbidity index (CCI),
antibiotic use before arrival, site of infection (e.g., lung,
abdomen, urinary tract, soft tissue, central nerve system,
or blood stream-related), sepsis-related organ failure as-
sessment (SOFA) score, and intravenous fluid bolus
completed within 3 h (30 mg/kg crystalloid). We also
performed the same analysis after replacing time to anti-
biotic as a continuous variable. In a subgroup analysis,
we stratified patients with septic shock and those from
only ED based on hospital admission source and ana-
lyzed these subgroups as described in the primary ana-
lysis [i.e., the GEE model adjusted patient age, gender,
CCI, antibiotic use before arrival, site of infection, SOFA
score, and intravenous fluid bolus completed within 3 h
(30 mg/kg crystalloid)].
All statistical analyses were performed using Stata soft-
ware version 15.1 (StataCorp, TX, USA).
Results
We recruited 1184 patients with severe sepsis who were
admitted to ICUs at participating institutions during the
FORECAST study period. Of these, 60 patients were ex-
cluded because of missing data on the timing of anti-
biotic administration (n = 11) or in-hospital mortality
(n = 33) or because the time to antibiotic was greater
than 1440min. Of the remaining 1124 participants who
were admitted to 54 hospitals, 30.5% of the patients re-
ceived antibiotics within 1 h, and 73.9% of the patients
received antibiotics within 3 h. Overall, the median time
to antibiotic administration was 102 min (IQR, 55–189),
and compared with patients diagnosed in the ED [90
min (IQR, 48–164 min)], time to antibiotic administra-
tion was shortest in patients diagnosed in ICUs [60 min
(39–180 min)] and longest in patients who had been
transferred from wards [120 min (62–226 min)], imply-
ing that patients diagnosed in the ED or the ICU re-
ceived antibiotics earlier than those in the ward.
Baseline characteristics, categorized based on the tim-
ing of antibiotic administration, are detailed in Table 1.
The 0–60, 61–120, and 121–180 min groups received
lower pre-antibiotic therapy, such as oral medicines for
infection, than the other groups. The 0–60, 61–120, and
121–180min groups were also more likely to achieve
the 3-h bundle, such as obtaining blood cultures and
intravenous fluid bolus than the other groups.
Overall crude mortality was 23.4% in the study popula-
tion. Crude mortalities were 27.7% and 16.2% among
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patients with and without shock, respectively. Patients
received antibiotics within the first 60 min had the high-
est rates of mortality (28.0%) and risk-adjusted mortality
[28.7% (95% CI 23.3–34.1); Table 2, Fig. 1], whereas that
of patients administered with antibiotics between 61 and
120 min had the lowest (20.2%) and risk-adjusted mor-
tality rates [21.6% (95% CI 16.5–26.6)]. Importantly,
mortality was different only between patients in the 0–
60 and 61–120 min groups. In addition, time to antibi-
otics as a continuous variable was not related to mortal-
ity, either (odds ratio 0.999 [0.997–1.000; P = 0.152]).
Subgroup analysis yielded a crude mortality rate of
27.7% in patients with septic shock, and patients in the
0–60 min group continued to have the highest mortality
(31.6%) and risk-adjusted mortality rates [30.0% (95% CI
23.5–36.5)], whereas those patients administered with
antibiotics between 361 and 1440min were the lowest
[21.6% (95% CI 11.1–32.0)]. In addition, the subgroup
analysis yielded a crude mortality rate of 21.9% in the
ED patients, and patients in the 0–60min group contin-
ued to have the highest mortality (29.1%) and risk-
adjusted mortality rates (27.9% [95% CI 21.1–34.6]),
whereas that in patients administered with antibiotics
between 361 and 1440min was the lowest [12.8% (95%
CI 5.7–25.0)].
Discussion
Summary
In emergency medical centers in Japan, one third of pa-
tients receive antibiotics within 1 h and three quarters
within 3 h of sepsis recognition. Although we have found
high levels of adherence to the sepsis care bundle (2012)
during the study period, we were unable to show a linear
relationship between the timing of antibiotic administra-
tion, such as within 1 h or 3 h after sepsis recognition,
and in-hospital mortality among patients with severe
sepsis and septic shock.
Comparison with previous studies
Although previous studies have shown that a delay in
antibiotic administration is associated with a higher in-
hospital mortality rate [10–14], our findings from a pro-
spective observational study obtained data of antibiotic
administration timing do not support their results. Nei-
ther prospective nor retrospective observational data can
establish causation, and discrepancies between these re-
sults only raise further questions. Interestingly, a meta-
analysis of studies regarding the relationship between
antibiotic administration timing and mortality found no
significant benefit after administering antibiotics within
1–3 h from triage or sepsis recognition in comparison
with administration at a later timing [15], and a RCT of
providing antibiotics to patients with suspected sepsis in
the ambulance did not show improved survival [7].
Nonetheless, these previous studies [7, 10–13] and the
present study have three major problems: (1) under-
standing the clinical courses of sepsis, including its on-
set; (2) stratification of sepsis severity and cognate
adjustments to treatment strategies, e.g., rapid treat-
ments; and (3) establishing correlation or causation in
sepsis care bundle studies.
Sepsis is different from other time-dependent and
emergent conditions such as acute coronary syndrome
because its precise onset is difficult to establish and the
lack of a specific diagnostic marker makes recognition
problematic. Three phases in the clinical course of sepsis
are recognized: (A) time from onset of infection to a
detectable condition, (B) time from a detectable condi-
tion to diagnosis, and (C) time from diagnosis to anti-
biotic administration (time to antibiotic), and although
phases A and B are significantly shorter in other time-
dependent emergent conditions, the duration of these
two phases varies considerably in sepsis. Furthermore, it
is difficult to focus only on phase C to reduce mortality
in sepsis as other variables that can affect outcomes in-
clude the timestamp of antibiotic initiation (time zero)
and patient location, as seen in previous studies [15] and
in our study. Similar to other studies, we defined time
zero as the time of sepsis recognition, although it is a
subjective choice [15], because the clinical course of
each patient would differ based on the presenting
symptoms, even if triage at ED is chosen as a reliable
time zero point [16]. Thus, detection of sepsis and anti-
biotic initiation are equally important as delays in ap-
propriate antibiotic therapy are more likely to occur in
patients with complex or atypical presentations who are
also more likely to harbor drug-resistant organisms
[17]. Moreover, reports show that inter-hospital trans-
fer delayed the administration of initial antibiotics, al-
though prognosis was not different [18]. Similar to
previous reports, our patients included not only those
presenting to ED but also those being transferred from
other hospitals [15], and it is essential to disentangle
such complicated definitions of time zero and locations
in each study before direct comparisons can be made
among these studies.
Sepsis severity stratification and adjustment with rapid
treatment may have been insufficient in previous and
our studies regarding time to antibiotic, and conflating
sepsis and septic shock may also be a confounder. Al-
though 63% of the patients in our study presented with
shock, we could not find any association between earlier
time to antibiotic and reduced mortality in all partici-
pants. Recent studies have demonstrated a weak associ-
ation between time to antibiotic therapy and mortality in
all cohorts (a relatively mild state in comparison with
our cohort), although a large significant association be-
tween delays in antibiotic administration and higher
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mortality rates in patients with septic shock [10, 11].
Further, an RCT of administering antibiotics to patients
with suspected sepsis in the ambulance also included
many patients without shock [7]. In the study, it notes
that even patients in the control group received antibi-
otics quite early and that the patients were treated with
low risk (mortality rate 8%). This is quite a different
population compared with that in the hospital setting.
Indeed, severity adjustment is difficult in sepsis studies
because sepsis includes complicated etiologies, various
presentations, and severities compared with other med-
ical emergencies [19]. Nevertheless, in our study, we
used fewer variables to adjust severity in comparison
with previous studies owing to the limitations of our
database [12, 13]. Previous studies have reported higher
crude mortality rates in patients administered with anti-
biotics in the first hour, which then declined over time;
however, severity adjustment reversed the relationship
between time to antibiotic and mortality [12, 13]. Our
study may also have been under-adjusted for severity be-
cause the sample size was relatively smaller and covari-
ates were fewer than those in previous studies [10–13].
Next, we must consider whether this relationship be-
tween time to antibiotic and mortality causative or only
a correlation, given that all other components of the
sepsis care bundle may be potentially physiologically ef-
fective along with time to antibiotic and that the effect-
iveness of each component remains controversial in
various settings [10, 20, 21]. Adherence to the sepsis
care bundle also varies in each setting [8, 10, 22, 23]. For
example, in a study among patients who received
antibiotics as they met the criteria for severe sepsis, a
relatively high compliance rate for the sepsis care bundle
was reported if sepsis was definitively diagnosed (with
diagnosis code) compared with undiagnosed sepsis
(without diagnosis code) [22]. In our study, the 0–60,
61–120, and 121–180 min groups were more likely to
comply with the 3-h bundle, compared with the others.
Conversely, the prognosis may have been good in pa-
tients who had been diagnosed early and in those who
were administered with antibiotics early [10–13], imply-
ing that diagnosing sepsis may be more important than
initiating the sepsis care bundle. Further, all components
of the bundle should be investigated in future studies
that focus on the relationship between time to antibiotic
and trigger of initiation.
Possible explanations and implications
Medical staff intuitively understands that the early use of
appropriate antibiotics is an important modifiable factor.
However, optimal timing and its effectiveness remain
unclear after a widespread implementation of the sepsis
protocol in developed countries such as Japan. Although
there is no doubt that sepsis care bundle components,
such as time to antibiotic, play a role in the arising im-
portance of treatment speed, a similar situation arose
when early goal-directed therapy was debated [24, 25].
In this study, patients who received antibiotics within
the first hour had the highest mortality despite the great-
est compliance with the entire 3-h bundle. This may be
because of the severity at presentation, detecting anti-
biotic use within the first hour, or an obvious septic
.1
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Fig. 1 Adjusted in-hospital mortality according to the timing of antibiotic administration among patients with severe sepsis and septic shock.
Adjusted by age, gender, admission source (emergency department, ward, or in intensive care unit), CCI, antibiotic use before arrival, site of
infection (e.g., lung, abdomen, urinary tract, soft tissue, central nerve system, or blood stream-related), SOFA score, and intravenous fluid bolus
completed within 3 h (30 mg/kg crystalloid)
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state. Alternatively, very early antibiotic use (within 1 h)
may lead to unfavorable outcomes; although, this does
not seem likely as all the patients would have had a sep-
sis state for some time before the point of recognition
[26]. Furthermore, indiscriminate and rapid use of
broad-spectrum antibiotics in all patients may be poten-
tially harmful [27, 28], as it may lead to adverse events;
however, there are only few reports on adverse events of
rapid use of antibiotics. Incorrect diagnosis of sepsis
may lead to a delay in administering other useful treat-
ments or appropriate source control despite the use of
broad-spectrum antibiotics [17].
Although there may be a linear relationship between
early time to antibiotic therapy and better prognosis in
sepsis, it is presumably weak. Moreover, similar to the
previous study report, our results showed that earlier
time to antibiotic therapy was related to better outcomes
in ED patients [14] when we excluded patients who re-
ceived antibiotics within 1 h. Otherwise, focusing on the
rapid use of antibiotics may lead to misdiagnosis of the
site of infection, which is related to poor outcomes [28].
Sepsis treatment and care involve components other
than the time to antibiotic, and while this does not mean
that rapid treatments are not good, most physicians in-
tuitively recognize the need for it. Thus, timely antibiotic
administration to patients with sepsis should remain one
of the key elements in the sepsis care bundle, regardless
of time restriction.
Limitations
This study has several limitations. First, controlling for
confounders may have been insufficient, as there are po-
tential unknown confounders not available to us. Anti-
biotic initiation can be determined not only based on
the patient’s severity but also on unknown factors that
are difficult to be quantified. Second, there were patients
who were using antibiotics before arrival. We have ad-
justed antibiotic use before arrival as a covariate in the
GEE models. Moreover, the results did not change sig-
nificantly even if patients with antibiotic usage before ar-
rival were excluded. Third, there may be an indication
bias as antibiotics may have been prescribed within the
first hour only in patients with severe (non-survivable)
presentation. However, we found that the results did not
change even if patients who died within 1, 2, or 3 days
were excluded from the analysis, suggesting that it may
be difficult to show differences in practice quality be-
tween patients presenting with considerably mild and
considerably severe symptoms [7]. Forth, there may have
been a social desirability bias, as physicians usually wish
to be evaluated as having responded to critical patients
first. Fifth, there may have been a ceiling effect with re-
spect to severity scores, because our study population
was more severely ill than those in previous studies.
Sixth, the timestamp of protocol initiation was defined
as at the time of sepsis recognition, which is relatively
later than the time of triage at ED. Our study may have
only shown a relationship between time to antibiotic
and in-hospital mortality if sepsis recognition occurred
early in the course of the disease. Seventh, we did not
have data about the appropriateness of antibiotic. How-
ever, as the first FORECAST paper [8] showed, 84% of
patients received broad-spectrum antibiotics within 3 h.
Most patients at least adhered to empiric antibiotics
based on the guideline. In addition, carbapenem was
most commonly used after initial diagnoses (55%)
followed by tazobactam/piperacillin (21%) and vanco-
mycin (18%). Thus, the important pathogens would have
been covered by the chosen antibiotics even if antibiotic-
resistant pathogens were present. Finally, the descriptive
nature of the study could not completely identify the
causal inference between the observed time to antibiotic
and in-hospital mortality. In this study, we described
sepsis care and implementation of sepsis bundle in Japan
as one of the high adherence countries of the sepsis
guideline. Our results suggested that this relationship is
still controversial, and RCT of this topic should be stud-
ied further.
Conclusions
Our prospective study failed to show a difference in in-
hospital mortality based on the timing of antibiotic admin-
istration. Future studies are needed to prove or refute
these results among patients with sepsis or septic shock.
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